These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36172377)

  • 1. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.
    Zhang C; Zeng M; Ge Y; Liu K; Xing C; Mao H
    Front Immunol; 2022; 13():977377. PubMed ID: 36172377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
    Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W; Kwok A
    Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z; Zhang C; Gao C; Li C; Li R; Zheng Z
    Arthritis Res Ther; 2024 Sep; 26(1):163. PubMed ID: 39294688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H; Chen C; Yang H; Tu J
    Eur J Pediatr; 2024 Sep; 183(9):3987-3995. PubMed ID: 38940925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K; Kurita N; Noma H; Matsuki T; Quasny H; Levy RA; Jones-Leone AR; Gairy K; Yajima N
    Lupus Sci Med; 2022 Sep; 9(1):. PubMed ID: 37017254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
    J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.
    Dimelow R; Liefaard L; Green Y; Tomlinson R
    Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.
    Plüß M; Piantoni S; Tampe B; Kim AHJ; Korsten P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2072143. PubMed ID: 35588699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
    Anders HJ; Furie R; Malvar A; Zhao MH; Hiromura K; Weinmann-Menke J; Green Y; Jones-Leone A; Negrini D; Levy RA; Lightstone L; Tanaka Y; Rovin BH
    Nephrol Dial Transplant; 2023 Nov; 38(12):2733-2742. PubMed ID: 37463054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.